DexCom (NASDAQ:DXCM) Price Target Raised to $90.00

DexCom (NASDAQ:DXCM) had its price target boosted by research analysts at Wells Fargo & Company from $85.00 to $90.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the medical device company’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 10.34% from the stock’s current price.

DXCM has been the subject of a number of other reports. Raymond James Financial reiterated a “strong-buy” rating on shares of DexCom in a research note on Friday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of DexCom in a report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price objective for the company. TD Cowen reiterated a “buy” rating and set a $95.00 target price (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Finally, Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $87.12.

DexCom Stock Up 9.4%

DXCM stock traded up $7.03 during mid-day trading on Friday, hitting $81.57. 3,612,379 shares of the company were exchanged, compared to its average volume of 5,200,281. The company has a market capitalization of $31.47 billion, a PE ratio of 34.99, a price-to-earnings-growth ratio of 1.24 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom has a twelve month low of $54.11 and a twelve month high of $87.00. The firm has a fifty day simple moving average of $72.91 and a 200 day simple moving average of $69.10.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s revenue was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.48 EPS. On average, research analysts forecast that DexCom will post 2.57 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the transaction, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the company’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This represents a 7.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,506 shares of company stock valued at $7,205,258 over the last three months. 0.28% of the stock is currently owned by company insiders.

Institutional Trading of DexCom

Several large investors have recently added to or reduced their stakes in DXCM. Norges Bank bought a new stake in DexCom during the 4th quarter valued at $483,356,000. AQR Capital Management LLC lifted its holdings in DexCom by 597.8% in the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock worth $205,932,000 after purchasing an additional 2,658,158 shares during the period. Employees Provident Fund Board bought a new position in DexCom in the 4th quarter valued at about $145,352,000. J. Stern & Co. LLP grew its position in DexCom by 2,114.8% in the 4th quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock valued at $106,323,000 after buying an additional 1,529,641 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of DexCom by 271.4% in the 1st quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock worth $129,699,000 after acquiring an additional 1,509,219 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom exceeded second-quarter expectations, reporting adjusted EPS of $0.70 versus the $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13% year over year, while EPS rose from $0.48 a year earlier. Reuters article
• Positive Sentiment: The company raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by sustained demand for continuous glucose monitoring devices. Management is targeting nearly 50% U.S. adoption of the G7 15-Day sensor by year-end. Seeking Alpha outlook article
• Positive Sentiment: Worldwide revenue growth included $933 million from the U.S., up 11%, with international sales also contributing to the overall 12% organic growth rate. The raised forecast and quarterly beat initially sent shares higher in extended trading. GuruFocus earnings highlights
• Positive Sentiment: UBS reaffirmed its Buy rating and maintained a $96 price target, implying substantial upside from the referenced share price. Benzinga analyst coverage
• Neutral Sentiment: Although the earnings news is favorable, the subsequent pullback may reflect profit-taking after the initial rally or investor caution about expectations at a valuation near 32 times earnings.
• Negative Sentiment: Medical-device companies continue to face potential margin pressure from tariffs and inflation, risks that could temper the benefit of strong underlying demand. Zacks medical-product outlook

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.